DR. SARAH D FOLSCROFT M.D.
Prescription History 1679795249
Internal Medicine in Kansas City, KS


Quality Rating: 91.89 out of 100 score

NPI Status: Active since May 03, 2007

Contact Information

3901 RAINBOW BLVD., 6040 DELP, MS 1020
DIVISION OF GENERAL AND GERIATRIC MEDICINE, UNIVERSITY
KANSAS CITY, KS
ZIP 66160
Phone: (913) 588-6005
Fax: (913) 588-3877

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. SARAH D FOLSCROFT M.D., an active Internal Medicine specialist practicing in Kansas City, KS. Our medical registry currently tracks 1 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 18 documented patient claims. Among these therapy options, the most frequently utilized medication is Eliquis, which accounts for 18 claims alone.

Medication Index

No matching medications currently found on file.

Eliquis

Generic Formulation: ApixabanSpecialty: Hospitalist
Provider Metrics Summary
Total Claims 18
30-Day Fills 22.0
Days Supply 660
KS State Average Benchmarks
Peer Average Claims85.0
Peer Average 30-Day Fills117.9
Peer Average Days Supply3,219
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 78.8% less volume than the regional standard for practitioners inside KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $12,880.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$715.56

State Avg Cost Per Claim

$703.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. SARAH D FOLSCROFT M.D. provides transparency into local medical care patterns within Kansas City, KS.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Internal Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.